[HTML][HTML] Amyloid precursor protein and Alzheimer's disease
KS Orobets, AL Karamyshev - International journal of molecular sciences, 2023 - mdpi.com
Alzheimer's disease (AD) is one of the most common neurodegenerative disorders
associated with age or inherited mutations. It is characterized by severe dementia in the late …
associated with age or inherited mutations. It is characterized by severe dementia in the late …
Recent research trends in neuroinflammatory and neurodegenerative disorders
J Cohen, A Mathew, KD Dourvetakis… - Cells, 2024 - mdpi.com
Neuroinflammatory and neurodegenerative disorders including Alzheimer's disease (AD),
Parkinson's disease (PD), traumatic brain injury (TBI) and Amyotrophic lateral sclerosis …
Parkinson's disease (PD), traumatic brain injury (TBI) and Amyotrophic lateral sclerosis …
Role of histone modifications in neurogenesis and neurodegenerative disease development
A Zhao, W Xu, R Han, J Wei, Q Yu, M Wang, H Li… - Ageing Research …, 2024 - Elsevier
Progressive neuronal dysfunction and death are key features of neurodegenerative
diseases; therefore, promoting neurogenesis in neurodegenerative diseases is crucial. With …
diseases; therefore, promoting neurogenesis in neurodegenerative diseases is crucial. With …
Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease
WM Su, XJ Gu, M Dou, QQ Duan, Z Jiang… - Journal of Neurology …, 2023 - jnnp.bmj.com
Background Alzheimer's disease (AD) is the leading cause of dementia. Currently, there are
no effective disease-modifying treatments for AD. Mendelian randomisation (MR) has been …
no effective disease-modifying treatments for AD. Mendelian randomisation (MR) has been …
Nanomedicine in the Management of Alzheimer's Disease: State-of-the-Art
SN Mir Najib Ullah, O Afzal, ASA Altamimi, H Ather… - Biomedicines, 2023 - mdpi.com
Alzheimer's disease (AD) is a deadly, progressive, and irreversible brain condition that
impairs cognitive abilities. Globally, it affects 32.6 million individuals, and if no viable …
impairs cognitive abilities. Globally, it affects 32.6 million individuals, and if no viable …
Unraveling the therapeutic potential of quercetin and quercetin-3-O-glucuronide in Alzheimer's disease through network pharmacology, molecular docking, and …
S Sabarathinam - Scientific Reports, 2024 - nature.com
Quercetin is a flavonoid with notable pharmacological effects and promising therapeutic
potential. Quercetin plays a significant role in neuroinflammation, which helps reduce …
potential. Quercetin plays a significant role in neuroinflammation, which helps reduce …
AI-driven innovations in Alzheimer's disease: Integrating early diagnosis, personalized treatment, and prognostic modelling
MB Kale, NL Wankhede, RS Pawar, S Ballal… - Ageing Research …, 2024 - Elsevier
Alzheimer's disease (AD) presents a significant challenge in neurodegenerative research
and clinical practice due to its complex etiology and progressive nature. The integration of …
and clinical practice due to its complex etiology and progressive nature. The integration of …
Promoting Alzheimer's disease research and therapy with stem cell technology
Z Cao, F Kong, J Ding, C Chen, F He… - Stem cell research & …, 2024 - Springer
Background Alzheimer's disease (AD) is a prevalent form of dementia leading to memory
loss, reduced cognitive and linguistic abilities, and decreased self-care. Current AD …
loss, reduced cognitive and linguistic abilities, and decreased self-care. Current AD …
SGLT2 inhibitors: A novel therapy for cognitive impairment via multifaceted effects on the nervous system
J Mei, Y Li, L Niu, R Liang, M Tang, Q Cai, J Xu… - Translational …, 2024 - Springer
The rising prevalence of diabetes mellitus has casted a spotlight on one of its significant
sequelae: cognitive impairment. Sodium-glucose cotransporter-2 (SGLT2) inhibitors …
sequelae: cognitive impairment. Sodium-glucose cotransporter-2 (SGLT2) inhibitors …
Mitochondria-targeted delivery strategy of dual-loaded liposomes for Alzheimer's disease therapy
L Vasileva, G Gaynanova, F Valeeva… - International journal of …, 2023 - mdpi.com
Liposomes modified with tetradecyltriphenylphosphonium bromide with dual loading of α-
tocopherol and donepezil hydrochloride were successfully designed for intranasal …
tocopherol and donepezil hydrochloride were successfully designed for intranasal …